Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it.
Brock P, Meijer A, Kogner P, Ansari M, Capra M, Geller J, Heuvel-Eibrink MVD, Knight K, Kruger M, Lindemulder S, Maibach R, O'Neill A, Papadakis V, Rajput K, Bleyer A, Bouffet E, Sullivan M. Brock P, et al. Pediatr Blood Cancer. 2023 May;70(5):e30248. doi: 10.1002/pbc.30248. Epub 2023 Feb 11. Pediatr Blood Cancer. 2023. PMID: 36772889 No abstract available.
Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.
Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, Rassekh SR, Chang KW, Fligor BJ, Rajput K, Sullivan M, Neuwelt EA. Brock PR, et al. J Clin Oncol. 2012 Jul 1;30(19):2408-17. doi: 10.1200/JCO.2011.39.1110. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547603 Free PMC article. Review.
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN). Ladenstein R, et al. Among authors: brock p. Lancet Oncol. 2017 Apr;18(4):500-514. doi: 10.1016/S1470-2045(17)30070-0. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28259608 Clinical Trial.
Hepatoblastoma in children aged less than six months at diagnosis: A report from the SIOPEL group.
Dall'Igna P, Brugieres L, Christin AS, Maibach R, Casanova M, Alaggio R, de Goyet JV, Zsiros J, Morland B, Czauderna P, Childs M, Aronson DC, Branchereau S, Brock P, Perilongo G. Dall'Igna P, et al. Among authors: brock p. Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26791. Epub 2017 Sep 18. Pediatr Blood Cancer. 2018. PMID: 28921839 Clinical Trial.
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Brock PR, et al. N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109. N Engl J Med. 2018. PMID: 29924955 Free PMC article. Clinical Trial.
The primary end point was the absolute hearing threshold, as measured by pure-tone audiometry, at a minimum age of 3.5 years. Hearing loss was assessed according to the Brock grade (on a scale from 0 to 4, with higher grades indicating greater hearing loss). ...Hearing los …
The primary end point was the absolute hearing threshold, as measured by pure-tone audiometry, at a minimum age of 3.5 years. Hearing loss w …
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
Freyer DR, Brock PR, Chang KW, Dupuis LL, Epelman S, Knight K, Mills D, Phillips R, Potter E, Risby D, Simpkin P, Sullivan M, Cabral S, Robinson PD, Sung L. Freyer DR, et al. Among authors: brock pr. Lancet Child Adolesc Health. 2020 Feb;4(2):141-150. doi: 10.1016/S2352-4642(19)30336-0. Epub 2019 Dec 19. Lancet Child Adolesc Health. 2020. PMID: 31866182 Free PMC article. Review.
Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
Berlanga P, Pasqualini C, Pötschger U, Sangüesa C, Castellani MR, Cañete A, Luksch R, Elliot M, Schreier G, Kropf M, Morgenstern D, Papadakis V, Ash S, Ruud E, Brock P, Wieczorek A, Kogner P, Trahair T, Ambros P, Boterberg T, Castel V, Valteau-Couanet D, Ladenstein R. Berlanga P, et al. Among authors: brock p. Eur J Cancer. 2021 Feb;144:1-8. doi: 10.1016/j.ejca.2020.10.020. Epub 2020 Dec 11. Eur J Cancer. 2021. PMID: 33316634 Free article. Clinical Trial.
287 results